Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers

Jeewandara, Chandima; Kamaladasa, Achala; Pushpakumara, Pradeep Darshana; Jayathilaka, Deshni; Aberathna, Inoka Sepali; Danasekara, Danasekara Rallage Saubhagya Rasikangani; Guruge, Dinuka; Ranasinghe, Thushali; Dayarathna, Shashika; Pathmanathan, Thilagaraj; Somathilake, Gayasha; Madhusanka, Panambara Arachchige Deshan; Ramu, Shyrar Tanussiya; Jayadas, Tibutius; Kuruppu, Heshan; Wijesinghe, Ayesha; Nimasha, Herath Mudiyanselage Thashmi; Milroy, Dushantha; Nandasena, Achini Anuja; Sanjeewani, Poththawela Kankanam Gamage Nilanka; Wijayamuni, Ruwan; Samaraweera, Sudath; Schimanski, Lisa; Tan, Tiong Kit; Dong, Tao; Ogg, Graham S.; Townsend, Alain; Malavige, Gathsaurie Neelika

doi:10.1038/s41467-021-24579-7

Cited by 53 publications

(72 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1C). In comparison, 66/68 (97.1%) who received a single dose of AZD1222 gave a positive response to sVNT assay, with median antibody levels of 69.42 (IQR 54.09 to 81.54 % of inhibition) as previously published 13 . We also compared the ACE2 receptor blocking antibody levels with baseline antibodies of those who were found to be infected, and in another cohort of 36 individuals who had varying severity of natural infection 17 .…”

Section: Seroconversion Rates To the Rst Dose Of Gam-covid-vacsupporting

confidence: 65%

“…It induced ACE2-receptor blocking antibodies in 82.6% of individuals and the levels were signi cantly lower than levels seen following a single dose of AZD1222 and those following natural infection. Therefore, the overall antibody responses following a single dose of Gam-COVID-Vac appear to be signi cantly lower than those following a single dose of AZD1222, especially in older individuals in a Sri Lankan population 13 .…”

Section: Discussionmentioning

confidence: 93%

“…The assay was carried out on baseline uninfected individuals (n = 69) and baseline infected individuals (n = 62); these were the same individuals used to assess ACE2 receptor blocking antibodies. The levels were compared with our previously published data 13 for those who received the AZD1222 at 4 weeks and additional assays were done for RBD antibodies for B.1.617.2 in this cohort as we had not assessed these antibodies previously. 13 compared to the rst dose of Gam-COVID-Vac, and for the S2 pool of peptides (p = 0.01).…”

Section: Antibodies To the Rbd Of The Ancestral Sars-cov-2 Virus And Variants Of Concernmentioning

confidence: 99%

“…The levels were compared with our previously published data 13 for those who received the AZD1222 at 4 weeks and additional assays were done for RBD antibodies for B.1.617.2 in this cohort as we had not assessed these antibodies previously. 13 compared to the rst dose of Gam-COVID-Vac, and for the S2 pool of peptides (p = 0.01).…”

Section: Antibodies To the Rbd Of The Ancestral Sars-cov-2 Virus And Variants Of Concernmentioning

confidence: 99%

“…Therefore, we studied antibody responses to the SARS-CoV-2 virus, antibodies to the receptor binding domain (RBD) of the ancestral Wuhan variant and other VOCs, ex vivo T cell responses and their functionality, and memory B cell responses in a large cohort of Sri Lankan individuals who received the rst dose of the Gam-COVID-Vac. In addition, in order to compare the immunogenicity of a single dose of the rAd26-S with another adenovirus vector vaccine, we compared the immunogenicity of this vaccine with previously published data of AZD1222 single dose responses at 4 weeks following vaccination in Sri Lankan individuals 13 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Immune Responses Following the First Dose of the Sputnik V (Gam-COVID-Vac)

Jeewandara¹,

Fernando²,

Pushpakumara³

et al. 2021

SSRN Journal

Self Cite

View full text Add to dashboard Cite

As the rst dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% seroconverted, with signi cantly lower seroconversion rates in those over 60 years (p = 0.004) and signi cantly lower than previously seen with AZD1222 (p = 0.018). 82.6% developed ACE2 receptor blocking antibodies, although levels were signi cantly lower than following natural infection (p = 0.0009) and a single dose of AZD1222 (p < 0.0001). Similar titres of antibodies were observed to the receptor binding domain of WT, B.1.1.7 and B.1.617.2 compared to AZD1222, while the levels for B.1.351 were signi cantly higher (p = 0.006) for Gam-COVID-Vac. 30% developed ex vivo IFNγ ELISpot responses (signi cantly lower than AZD1222), and high frequency of CD107a expressing T cells along with memory B cell responses. Although single dose of Gam-COVID-Vac was highly immunogenic, administration of a second dose is likely to be bene cial.

show abstract

Section: Seroconversion Rates To the Rst Dose Of Gam-covid-vacsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 93%

Section: Antibodies To the Rbd Of The Ancestral Sars-cov-2 Virus And Variants Of Concernmentioning

confidence: 99%

Section: Antibodies To the Rbd Of The Ancestral Sars-cov-2 Virus And Variants Of Concernmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immune Responses Following the First Dose of the Sputnik V (Gam-COVID-Vac)

Jeewandara¹,

Fernando²,

Pushpakumara³

et al. 2021

SSRN Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer?

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is a highly contagious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This deadly infection has resulted in more than 5.2 million deaths worldwide. The global rollout of COVID‐19 vaccines has without doubt saved countless lives by reducing the severity of symptoms for patients. However, as the virus continues to evolve, there is a risk that the vaccines and antiviral designed to target the infection will no longer be therapeutically viable. Furthermore, there remain fears over both the short and long‐term side effects of repeat exposure to currently available vaccines. In this review, we discuss the pros and cons of the vaccine rollout and promote the idea of a COVID medicinal toolbox made up of different antiviral treatment modalities, and present some of the latest therapeutic strategies that are being explored in this respect to try to combat the COVID‐19 virus and other COVID viruses that are predicted to follow. Lastly, we review current literature on the use of siRNA therapeutics as a way to remain adaptable and in tune with the ever‐evolving mutation rate of the COVID‐19 virus.

show abstract

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals

Jeewandara

Aberathna

Gomes

et al. 2022

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

Background: To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing gaps. Methods: Antibodies to the SARS-CoV-2 virus were assessed in 297 individuals with a dosing gap of 12 weeks, sampled 12 weeks post second dose (cohort 1) and in 77 individuals with a median dosing gap of 21.4 weeks (cohort 2) sampled 6 weeks post second dose. ACE2-blocking antibodies (ACE2-blocking Abs), antibodies to the receptor-binding domain (RBD) of variants of concern (VOC), and ex vivo T cell responses were assessed in a subcohort. Results: All individuals (100%) had SARS-CoV-2-specific total antibodies and 94.2% of cohort 1 and 97.1% of cohort 2 had ACE2-blocking Abs. There was no difference in antibody titers or positivity rates in different age groups in both cohorts. The ACE2-blocking Abs (p < .0001) and antibodies to the RBD of the VOCs were significantly higher in cohort 2 compared to cohort 1. 41.2% to 65.8% of different age groups gave a positive response by the hemagglutination assay to the RBD of the ancestral virus and VOCs in cohort 1, while 53.6%-90% gave a positive response in cohort 2. 17/57 (29.8%) of cohort 1 and 17/29

show abstract

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers

Cited by 53 publications

References 27 publications

Immune Responses Following the First Dose of the Sputnik V (Gam-COVID-Vac)

Immune Responses Following the First Dose of the Sputnik V (Gam-COVID-Vac)

Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer?

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals

Contact Info

Product

Resources

About